BETA
Your AI-Trained Oncology Knowledge Connection!
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, break down the latest data trends in platinum-resistant ovarian cancer.
EP. 1: Current Treatment Approaches and Challenges in Platinum-Resistant Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.
EP. 2: MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
EP. 3: PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
EP. 4: Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.
EP. 5: Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.
EP. 6: Ongoing Research to Watch in Ovarian Cancer in 2025
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.
Zongertinib Yields Clinical Benefit in Previously Treated, HER2-Mutated, Advanced NSCLC
Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC
Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity
First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma